John Rebchook

DEA removes cannabis drug Epidiolex from controlled substance list

Epidiolex, the only plant-derived cannabis drug approved by the U.S. Food and Drug Administration, is no longer considered a controlled substance, providing a boost to its manufacturer’s stock price. GW Pharmaceuticals, a biopharmaceutical company based in London, saw its stock go up 5.9% on Tuesday, one day after the U.S. Drug Enforcement Administration said it […]

Read More

Australis backs out of deal for Colorado hemp firm Folium

Australis Capital, a cannabis investment firm based in Las Vegas, terminated its planned acquisition of hemp company Folium Biosciences in the wake of lurid headlines that surfaced regarding the Colorado company it was going to purchase only two months ago. Australis, a spin-off of Canadian marijuana producer Aurora Cannabis, said in a news release it […]

Read More

California hemp and cannabis testing lab raises $22.6 million

Cannalysis, a hemp and cannabis testing lab based in California, raised $22.6 million that it said will fund its expansion in the state as well as helping it to move into other marijuana markets in the U.S. The Santa Ana-based company raised the money from Canlab, a cannabis, hemp and CBD testing laboratory network. The […]

Read More